12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Patiromer: SPA received

Relypsa said it reached an agreement with FDA for an SPA for a 2-part Phase III trial of patiromer in about 240 patients. The trial is slated to begin...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >